Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Uma H AthaleManeka PuligandlaKristen E StevensonBarbara AsselinLuis A ClavellPeter D ColeKara M KellyCaroline LaverdiereJean-Marie LeclercBruno MichonMarshall A SchorinMaria Luisa SulisJennifer J G WelchMarian H HarrisDonna S NeubergStephen E SallanLewis B SilvermanPublished in: Pediatric blood & cancer (2018)
The low rates of relapse and TRM indicate that uniform risk-stratified therapy for DS-ALL and non-DS-ALL patients on DFCI ALL Consortium protocols was safe and effective, although the increased rate of toxicity in the DS-ALL patients highlights the importance of supportive care during therapy.
Keyphrases
- end stage renal disease
- acute lymphoblastic leukemia
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- prognostic factors
- patient reported outcomes
- mesenchymal stem cells
- pain management
- acute myeloid leukemia
- papillary thyroid
- young adults
- allogeneic hematopoietic stem cell transplantation
- chronic pain